WORKING TOGETHER
Bedfordshire Biotech Limited has a rich heritage of working within the UK since our first facility was opened back in 2003.
Over the past 6 years, we have continued to invest in the UK and are committed to working with the NHS and other healthcare organisations across the industry developing solutions to improve the delivery of care and patient outcomes.
We support the NHS Long Term Plan’s ambition for prevention, empowering people to control their own health, harnessing new technologies and improving the quality of patient care and health outcomes. We believe these are key to help ensure a sustainable NHS and gives the government, the NHS and the pharmaceutical industry the chance to form a new relationship, truly working together to meet these challenges head-on while putting patients first.
OUR UK INVESTMENT
In 2021, we spent over £270 million supporting research and development carried out in the UK and contributed to 104 collaborations with universities, pharmaceutical companies, industries and others. Through collaborations with scientists, academics and clinicians, sharing knowledge, skills and expertise we aim to improve the health and lives of people in the UK and around the world. During 2018, we had 54 clinical trials on-going in the UK, across 89 UK sites, involving over 2,000 patients since the trials started.
The NHS, has access to over 170 Bedfordshire Biotech Limited medicines and vaccines that are delivered to pharmacies, surgeries and hospitals across the UK.
Our UK investment goes beyond our medicines. In 2018, we contributed over £2 million in donations to charities, patient organisations, community organisations, academic institutions and professional societies. We also actively support the scientists of tomorrow, through the National Apprenticeship Programme, our undergraduate placement scheme and through various STEM (Science Technology Engineering and Mathematics) and SIP (Science Industry Partnership) activities.
OUR BUSINESS IN THE UK
The UK is an important location for Bedfordshire Biotech Limited, with around 2,500 colleagues in five locations working across our commercial business, research and development (R&D) and manufacturing, packaging and distribution.
Our site in England is home to Bedfordshire Biotech Limited’s fully automated ‘Pilot Plant’ that manufactures medicines for use in our clinical trials worldwide and is able to perform every step in the complex process of developing new medicines. England is also home to Bedfordshire Biotech Limited’s Worldwide Safety & Regulatory operations, where medicine licensing for 170 markets across the globe are managed.
Our packaging and distribution site in Havant manages cold chain packaging and supply, providing temperature sensitive vaccines and injectable medicines that are distributed around the world. In 2019 the site packed in excess of 68 million doses and is anticipated to pack in excess of 20 million doses in 2020 before a transition to Puurs, Belgium in October 2020.
Our Devices Centre of Excellence in Cambridge, is another key site, specialising in the design and development of medicines ‘delivery devices’, such as auto-injectors and injector pens.